Market Research Report
Hemostasis And Tissue Sealing Agents Market Size, Share & Trends Analysis Report By Product (Topical Hemostat, Adhesives & Tissue Sealant), By Region, And Segment Forecasts, 2019 - 2026
|Published by||Grand View Research, Inc.||Product code||355228|
|Published||Content info||15 Pages
Delivery time: 2-3 business days
|Hemostasis And Tissue Sealing Agents Market Size, Share & Trends Analysis Report By Product (Topical Hemostat, Adhesives & Tissue Sealant), By Region, And Segment Forecasts, 2019 - 2026|
|Published: February 28, 2019||Content info: 15 Pages||
The global hemostasis and tissue sealing agents market size is expected to reach USD 10.34 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 8.7% during the forecast period. The agents have gained popularity over time due to their ability to prevent blood loss. Rapid growth of minimal invasive technology and demand for faster recovery by patients is expected to promote market growth over the forecast period.
According to the Centers for Disease Control and Prevention (CDC), approximately 150 million of American population is currently suffering from at least one chronic condition, which leads to surgeries and even mortality at times. An estimate over the rising incidence was made by the CDC, which concluded that over 48% of the entire American population is expected to suffer by chronic condition.
The hemostasis and tissue sealing agents market is expected to witness lucrative growth over the next seven years owing to, an increase in demand supported by rising surgery volumes. Growth in geriatric population and prevalence of chronic conditions are the impact rendering drivers for this industry.
Some key players operating in the hemostasis and tissue sealing agents market include: Johnson & Johnson; CryoLife Inc.; Pfizer; C R Bard; B Braun; Covidien; and Smith & Nephew. Market participants are involved in technological advancements to ensure sustainability and regional presence.
For instance, in March 2015, Ethicon announced higher efficiency of EVARREST fibrin sealant patch as compared to its substitute, TachoSil patch (Baxter). Further study would be conducted at the St. Vincent Heart Centre of Indiana to understand added advantages that the product can offer.